Clinical trial

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

NCT03894007

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2019-05-23

PhasePHASE2

Study timeline

Study start (actual)2019-05-23Date precision: day

Registry last updated2021-09-23

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Early-stage Breast Cancerunresolved

HER2-positive Breast Cancerunresolved

Interventions

DocetaxelDRUG · verified · RxNorm: docetaxel

CarboplatinDRUG · verified · RxNorm: carboplatin

TrastuzumabDRUG · verified · RxNorm: trastuzumab

PertuzumabDRUG · verified · RxNorm: pertuzumab

EpirubicinDRUG · verified · RxNorm: epirubicin

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

AtezolizumabDRUG · verified · RxNorm: atezolizumab

Trastuzumab emtansineDRUG

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

Renske Altenalead sponsor

Mapped research locations

StockholmSweden3 GothenburgSweden1 MalmöSweden1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03894007 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.